Singapore’s MiRXES raises US$77m to treble valuation as biotech craze catches on

MiRXES, a cancer diagnostics business based in Singapore, has secured US$77 million in a Series C round from investors as it seeks to commercialize its early cancer detection test kits around the world./nRead More